Board approved SP Analytics signing deal to acquire majority cash stake in Bion Therapeutics, to close by 30 Nov 2026. Bion H1 turnover Rs28.22 Cr. Funding via IPO GCP proceeds and debt. Another small bolt-on after recent injectable and R&D buys, but first branded prescription deal housed in R&D vehicle; extends acquisition-led build alongside export CDMO pivot. Price based on independent valuation and exact stake undisclosed; promoter interest and funding split between GCP and debt not disclosed; related-party assessment pending; closes within two weeks.
Sai Parenterals Renews AUD 30 Million Australian OTC Supply Agreement
Sai Parenterals Renews ₹204 Crore Australian OTC Supply Agreement
Sai Parenterals Redirects ₹83.83 Crore IPO Proceeds To Saicriti Acquisition
Sai Parenterals Approves ₹101.86 Crore IPO Proceeds Shift Into Two Pharma Acquisitions
Sai Parenterals Subsidiary Bags AUD 202 Million OTC Supply Deal